Skip to main content
    I

    ImmuCell Corporation (ICCC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $11.42
    +0.67 (+6.23%)

    Market Cap: $97.73M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    ImmuCell Corporation (ICCC) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    ImmuCell (ICCC) is expected to report earnings on Mar 2, 2027. In the quarter ended Sep 30, 2026, ImmuCell reported EPS of $0.10. It beat the EPS estimate in 2 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    25%(2/8)
    Avg Surprise
    +26.88%

    Next Report

    ICCC has an expected report date of Mar 2, 2027.

    ICCC Earnings Call

    The latest ICCC earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 8 quarters below that had an estimate, ICCC beat 2, missed 1 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $8.04M, up 45.9% from $5.51M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.10N/AN/AN/AN/AN/AN/AN/ANov 12, 2026$8.04M
    Jun 30, 2026$0.20N/AN/AN/AN/A+233.3%N/AN/AAug 13, 2026$7.19M
    Mar 31, 2026$0.21N/AN/AN/AN/A+33.2%N/AN/AMay 14, 2026$10.36M
    Dec 31, 2025-$0.31N/AN/AN/AN/A-646.7%N/AN/AMar 4, 2026$7.63M
    Sep 30, 2025-$0.02N/AN/AN/AN/AN/AN/AN/ANov 13, 2025$5.51M
    Jun 30, 2025$0.06N/AN/AN/AN/AN/AN/AN/AAug 14, 2025$6.44M
    Mar 31, 2025$0.16N/AN/AN/AN/AN/AN/AN/AMay 14, 2025$8.07M
    Dec 31, 2024$0.06N/AN/AN/AN/AN/AN/AN/AFeb 25, 2025$7.75M
    Sep 30, 2024-$0.09N/AN/AN/AN/AN/AN/AN/ANov 13, 2024$6.01M
    Jun 30, 2024-$0.20N/AN/AN/AN/A-208.9%N/AN/AAug 13, 2024$5.47M
    Mar 31, 2024-$0.06N/AN/AN/AN/AN/AN/AN/AMay 14, 2024$7.26M
    Dec 31, 2023-$0.15N/AN/AN/AN/AN/AN/AN/AFeb 27, 2024$5.10M
    Sep 30, 2023-$0.12N/AN/AN/AN/AN/AN/AN/ANov 13, 2023$5.40M
    Jun 30, 2023$0.18N/AN/AN/AN/AN/AN/AN/AAug 10, 2023$3.53M
    Mar 31, 2023-$0.30N/AN/AN/AN/A-433.3%N/AN/AMay 11, 2023$3.45M
    Dec 31, 2022-$0.32N/AN/AN/AN/AN/AN/AN/AFeb 21, 2023$3.91M
    Sep 30, 2022-$0.08N/AN/AN/AN/A-523.0%N/AN/ANov 21, 2022$4.80M
    Jun 30, 2022-$0.09N/AN/AN/AN/A-550.0%N/AN/AAug 11, 2022$3.86M
    Mar 31, 2022$0.09N/AN/AN/AN/AN/AN/AN/AMay 12, 2022$6.00M
    Dec 31, 2021-$0.01-$0.01N/A0.00%In line-133.3%N/AN/AFeb 22, 2022$5.44M
    Sep 30, 2021$0.02$0.02N/A0.00%In lineN/AN/AN/ANov 15, 2021$5.15M
    Jun 30, 2021$0.02$0.02N/A0.00%In lineN/AN/A0 up, 0 downAug 12, 2021$4.54M
    Mar 31, 2021-$0.06-$0.06N/A0.00%In lineN/AN/A0 up, 0 downMay 13, 2021$4.11M
    Dec 31, 2020$0.03-$0.04N/A+175.00%BeatN/AN/AN/AFeb 22, 2021$3.74M
    Sep 30, 2020-$0.04-$0.08-$0.08 - -$0.08+50.00%BeatN/A1N/ANov 12, 2020$3.72M
    Jun 30, 2020-$0.11-$0.10-$0.10 - -$0.10-10.00%MissN/A1N/AAug 12, 2020$2.97M
    Mar 31, 2020-$0.02-$0.02N/A0.00%In line-166.7%N/AN/AMay 13, 2020$4.91M
    Dec 31, 2019-$0.06N/AN/AN/AN/AN/AN/AN/AFeb 18, 2020$3.63M
    Sep 30, 2019-$0.07N/AN/AN/AN/AN/AN/AN/ANov 11, 2019$2.97M
    Jun 30, 2019-$0.09N/AN/AN/AN/AN/AN/AN/AAug 12, 2019$2.71M
    Mar 31, 2019$0.03N/AN/AN/AN/AN/AN/AN/AMay 13, 2019$4.41M
    Dec 31, 2018-$0.19N/AN/AN/AN/AN/AN/AN/AFeb 13, 2019$2.94M
    Sep 30, 2018-$0.05N/AN/AN/AN/AN/AN/AN/ANov 13, 2018$2.15M
    Jun 30, 2018-$0.15N/AN/AN/AN/AN/AN/AN/AAug 13, 2018$3.01M
    Mar 31, 2018-$0.04N/AN/AN/AN/A-133.3%N/AN/AMay 14, 2018$2.88M
    Dec 31, 2017-$0.05N/AN/AN/AN/A-906.5%N/AN/AFeb 8, 2018$3.13M
    Sep 30, 2017-$0.07N/AN/AN/AN/A-964.2%N/AN/ANov 13, 2017$2.00M
    Jun 30, 2017-$0.05N/AN/AN/AN/AN/AN/AN/AAug 14, 2017$1.75M
    Mar 31, 2017$0.12N/AN/AN/AN/A+4.6%N/AN/AMay 11, 2017$3.54M
    Dec 31, 2016$0.01N/AN/AN/AN/A-93.2%N/AN/AFeb 9, 2017$2.21M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.11, after -$0.28 the year before. It was $0.13 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.11N/A
    Dec 31, 2024-$0.28N/A
    Dec 31, 2023-$0.39N/A
    Dec 31, 2022-$0.40N/A
    Dec 31, 2021-$0.03N/A
    Dec 31, 2020-$0.14N/A
    Dec 31, 2019-$0.19N/A
    Dec 31, 2018-$0.43N/A
    Dec 31, 2017-$0.05-139.4%
    Dec 31, 2016$0.13N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,100 words across 7 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,1137
    2026Q2Jun 30, 20264,0728
    2026Q1Mar 31, 20263,6787
    2025Q4Dec 31, 20253,2104
    2025Q3Sep 30, 20253,3577
    2025Q2Jun 30, 20254,5836
    2025Q1Mar 31, 20254,0687
    2024Q4Dec 31, 20242,8094

    2026Q3 Earnings Call

    Opening remarks

    Joe Diaz Investor Relations Consultant Thank you, operator. Good morning, and welcome. As the operator indicated, my name is Joe Diaz with Lytham Partners. We are the investor relations consulting firm for ImmuCell. I thank all of you for joining us today to discuss the unaudited earnings for the third quarter and nine months ended September 30, 2026. Listeners are reminded and cautioned that statements made by management during the course of this call include forward-looking statements, which include any statement that refers to future events or expected future results or predictions about steps the company plans to take in the future. These statements are not guarantees of performance and are subject to risks and uncertainties that could cause actual results, outcomes, or events to differ materially from those discussed today. Additional information regarding forward-looking statements and the risks and uncertainties that could impact future results, outcomes, or events is available under the cautionary note regarding forward-looking statements provided with the press release that the company filed last night, along with the company's other periodic filings with the SEC. Information discussed on today's call speaks only as of today, Friday, November 13, 2026. The company undertakes no obligation to update any information discussed on today's call. Please note that references to certain non-GAAP financial measures may be made during today's call. With that said, let me turn the call over to Olivier te Boekhorst, President and CEO of ImmuCell Corporation, for some opening remarks. Olivier?

    Olivier te Boekhorst President and CEO Thanks, Joe, and good morning, everyone. It's my pleasure to welcome you today to the discussion of ImmuCell's results for the third quarter of 2026. Our discussion of results will be accompanied by a few key slides that are also part of our updated investor presentation. You can find that on our investor page, immucell.com/investors. I will start off today's call with a quick summary of ImmuCell's strategy, which we have developed and refined over the past year. We made the decision in December of 2025 to focus exclusively on First Defense, our bovine scours preventative product line, to take advantage of attractive market tailwinds. High calf values drive producer interest in effective preventatives, and we saw significant opportunity for growth in the U.S. and future international markets. We stopped investing in a new product for subclinical mastitis called Re-Tain, also driven by our contract manufacturer's inability to obtain GMP approval from the FDA. Our mission became to ensure we had sufficient supply to meet demand for First Defense and to restore our customers' confidence in that ability to supply after a protracted period of supply challenges leading to back orders. We invested in leadership, in expanding our commercial team, in colostrum sourcing capabilities, and importantly, in manufacturing.

    Frequently Asked Questions About ICCC

    When is ImmuCell's next earnings date?

    ImmuCell's next earnings report is expected for Mar 2, 2027.

    How often does ICCC beat earnings estimates?

    ImmuCell beat the EPS estimate in 2 of the 8 most recent quarters that had an estimate, with an average surprise of +26.88%.